A recent retrospective study led by Dr. Marilyn J. Siegel and her team at the Washington University School of Medicine in St. Louis has shed light on a critical issue in cancer care: routine clinical reads are more prone to overdiagnosing progressive disease when compared to RECIST 1.1 interpretations. This discrepancy holds significant implications, potentially leading to the premature discontinuation of effective treatments for cancer clinical trial participants and patients under standard care.
In this study, mint Lesion software was utilized for the criteria-based reads, determining overall response assessments according to RECIST 1.1 criteria, and generating structured reports for the clinical trial's principal investigator.
To learn more about the study's insights into the discrepant assessments and the suggested steps for mitigating this issue, click here.
Study Discovers Overdiagnosis of Progressive Cancer in Routine Clinical Evaluations
Related Resources
Related Resources
RACOON - What's Next?
Since mid-2020, mint Lesion™ has been successfully used within the Radiological Cooperative Network (RACOON), in the University Medicine Network which…
Structure, Gather, and Share Data Faster with the mint Lesion™ Browser-Based Application
Whether in clinical routine, in clinical trials or in clinical research, mint Lesion™ is a reliable and strong supporter of its users’ individual…
RACOON: A revolutionary project with all German university hospitals in the University Medicine Network (NUM)
The idea of aggregating clinical data from different sources, processing it in a structured way and using it for joint research may not be new, but…